8-K
Glucotrack, Inc. (GCTK)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): November 22, 2022
GLUCOTRACK,
INC.
(Exact name of registrant as specified in its charter)
| Delaware | 0-54785 | 98-0668934 |
|---|---|---|
| (State<br> or Other Jurisdiction | (Commission | (IRS<br>Employer |
| of<br> Incorporation) | File<br> Number) | Identification<br> No.) |
| 8<br> Ariel Sharon Street, P.O. Box 6037607, Or Yehuda, Israel | L3<br> 7760049 | |
| --- | --- | |
| (Address<br> of principal executive offices) | (Zip<br> Code) |
Registrant’s
telephone number, including area code: 972 (8) 675-7878
N/A
(Former name or former address, if changed since last report)
Securities
registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| None. |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 22, 2022, Nasdaq provided notice that pursuant to Nasdaq Listing Rule 5550(b)(1), GlucoTrack, Inc. (the “Company”) is required to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. Since its 10-Q for the period ended September 30, 2022 reported stockholders’ equity of $2,355,000, and as of November 22, 2022, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations, the Company no longer complies with the Rule. The Company has a 45-day period ending on January 6, 2023 to submit a plan of compliance to Nasdaq.
ITEM9.01 Exhibit
| Exhibit<br> 104 | Cover Page Interactive<br> Data File (embedded within the Inline XBRL document) |
|---|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 25, 2022
| GLUCOTRACK, INC. | |
|---|---|
| By: | /s/ Jolie Kahn |
| Name: | Jolie Kahn |
| Title: | Chief<br> Financial Officer |